Shawn Kwatra, M.D., Joseph W. Burnett endowed professor and chair of dermatology at the University of Maryland School of ...

Mona Shahriari, M.D., dermatologist at Central Connecticut Dermatology and an associate clinical professor at Yale School of Medicine discusses the highlights of her session called ‘Seeing Clearly: A ...

The FDA has granted nemolizumab Priority Review for the treatment of prurigo nodularis. The Food and Drug Administration (FDA) has accepted for review the Biologics License Applications (BLA) for ...

Despite the approval of dupilumab (Dupixent) in September 2022, there is an ongoing dearth of clinically effective treatments for prurigo nodularis, prompting the present investigation of the ...

Please provide your email address to receive an email when new articles are posted on . By week 12, itch and pain scores decreased 78.3% and 53.7% in the prurigo nodular and chronic pruritus of ...

Please provide your email address to receive an email when new articles are posted on . Regulatory authorities in four countries have accepted nemolizumab filings indicated for prurigo nodularis and ...

ZUG, Switzerland--(BUSINESS WIRE)--Galderma today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion and ...

As per the report published by DATAM Intelligence. The global prurigo nodularis treatment market is estimated to grow at a CAGR of 3.6% during the forecast period (2022-2029) to reach a decent value ...